Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

by Zacks Equity Research

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Brokers Suggest Investing in Medpace (MEDP): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Medpace (MEDP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

by Zacks Equity Research

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity

by Zacks Equity Research

Elevance Health, Medpace and Doximity are part of the Zacks Industry Outlook article.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Urmimala Biswas headshot

3 Medical Services Industry Stocks to Buy as Nursing Market Booms

by Urmimala Biswas

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, MEDP and DOCS are set to gain the most. However, staffing shortages continue to put brakes on growth.

Medpace (MEDP) Beats Q1 Earnings Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 30.61% and 0.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.

Why You Should Add Ensign Group (ENSG) to Your Portfolio Now

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.

Will Medpace (MEDP) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree

by Zacks Equity Research

Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Sharecare, Inc. (SHCR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sharecare (SHCR) delivered earnings and revenue surprises of -200% and 7.56%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Should You Add Universal Health (UHS) to Your Portfolio?

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on growing patient volumes at its acute care and behavioral healthcare facilities, acquisitions and a commendable financial stand.

Brookdale (BKD) February 2024 Weighted Average Occupancy Rises

by Zacks Equity Research

Brookdale (BKD) witnesses a continuous streak of 28 months of year-over-year improvements in the weighted average occupancy level.